Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 3 1Phase 1 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Breast Neoplasms 20Pancreatic Neoplasms 19Carcinoma, Non-Small-Cell Lung 17Ovarian Neoplasms 16Fallopian Tube Neoplasms 12Triple Negative Breast Neoplasms 10Neoplasm Metastasis 10Carcinoma, Ovarian Epithelial 10Unspecified Adult Solid Tumor, Protocol Specific 8Neoplasms 7Lung Neoplasms 7Endometrial Neoplasms 7Esophageal Neoplasms 6Brenner Tumor 6Breast Neoplasms, Male 6Stomach Neoplasms 5Melanoma 5Squamous Cell Carcinoma of Head and Neck 4Peritoneal Neoplasms 3Gallbladder Neoplasms 3Cholangiocarcinoma 3Adenocarcinoma of Lung 3Adenocarcinoma 3Uterine Cervical Neoplasms 2Urinary Bladder Neoplasms 2Salivary Gland Neoplasms 2Prostatic Neoplasms 2Precursor Cell Lymphoblastic Leukemia-Lymphoma 2Lymphoma, Non-Hodgkin 2Leukemia, Lymphocytic, Chronic, B-Cell 2

Interventions

nilotinib 1lorcaserin 1Taxes 1Paclitaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Anatomic Stage I Breast Cancer AJCC v8 × Taxes × Clear all
NCT04205903 2025-06-29

Nilotinib in Preventing Paclitaxel-Induced Peripheral Neuropathy in Patients With Stage I-III Breast Cancer

Ohio State University Comprehensive Cancer Center

Phase 1 Completed
11 enrolled 9 charts
Breast

Anatomic Stage I Breast Cancer AJCC v8

Data powered by HemOnc (CC BY 4.0) Colophon âš¡